The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1397855
This article is part of the Research Topic The Role of Immunotherapy in Urothelial Cancer View all 5 articles
Case Report: Toripalimab plus Anlotinib in Postoperative Recurrent Renal Pelvic Sarcomatoid Urothelial Carcinoma
Provisionally accepted- 1 Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
- 2 Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong Province, China
Background: Sarcomatoid urothelial carcinoma (SUC) is a rare renal malignancy. Its biological malignancy is high, the prognosis is poor, diagnostic and treatment options are few, and there is no standard treatment plan.Case Presentation: In this case, a 64-year-old woman was hospitalized with fever and lower back pain one week previously. The preliminary diagnosis was a right kidney stone with a urinary tract infection. After the anti-infection treatment, a percutaneous right nephrostomy was performed. The intraoperative biopsy (renal pelvis) finding was infiltrating urothelial carcinoma with a sarcomatoid variation. Subsequently, radical surgery was performed for cancer of the right renal pelvis. Implant metastasis of the abdominal wall and adjacent abdominal cavity occurred half a month after the surgery. The lesion was resected again, and two cycles of doxorubicin plus carboplatin chemotherapy were administered. However, the disease progressed more rapidly after the chemotherapy. With the written consent of the patient, the treatment was altered to targeted immune therapy with toripalimab plus anlotinib. A clinical cure was achieved after nine cycles of treatment with no obvious lesions on imaging. The maintenance therapy was administered consecutively for over a year, and the patient is at present still in good condition with a disease-free survival exceeding two years.This case proves that the combination of toripalimab and anlotinib is effective in the treatment of recurrent renal SUC. To the best of our knowledge, this is the first reported case of a patient with advanced recurrent urothelial carcinoma of the renal pelvis sarcomatoid cured with this therapy.
Keywords: Toripalimab, Anlotinib, Postoperative recurrence, renal pelvic urothelial carcinoma, upper-tract urothelial carcinoma, sarcomatoid urothelial carcinoma, Immune checkpoint inhibitor, tyrosine kinase inhibitor
Received: 10 Apr 2024; Accepted: 05 Sep 2024.
Copyright: © 2024 Hu, Deng, Pan, Zhang, Ruan, Jiang, Shen, Zhao and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lin Deng, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Guozhen Zhang, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Xiaolan Ruan, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Xinlan Jiang, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Hao Shen, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Lei Zhao, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Jun Dong, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, 510060, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.